Perioperative BRAF inhibitors in locally advanced stage III melanoma-Reference-Cited by-同舟云学术

Perioperative BRAF inhibitors in locally advanced stage III melanoma

Published:2017-06-26 Issue:7 Volume:116 Page:856-861
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Zippel Douglas¹²^ORCID,Markel Gal²³,Shapira-Frommer Roni²³,Ben-Betzalel Guy²³,Goitein David¹²,Ben-Ami Eytan²³,Nissan Aviram¹²,Schachter Jacob²³,Schneebaum Schlomo²⁴

Affiliation:

1. Department of Surgery C; Chaim Sheba Medical Center; Ramat Gan Israel

2. Sackler School of Medicine; Tel Aviv University; Tel Aviv Israel

3. Department of Oncology; Chaim Sheba Medical Center; Ramat Gan Israel

4. Department of Surgery; Tel Aviv Sourasky Medical Center; Tel Aviv Israel

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.24744/fullpdf

Reference35 articles.

1. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases;Balch;J Clin Oncol,2010

2. Staging and prognosis of cutaneous melanoma;Dickson;Surg Oncol Clin N Am,2011

3. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial;Eggermont;Lancet,2008

4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

5. Pathways and therapeutic targets in melanoma;Shtivelman;Oncotarget,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term efficacy of neoadjuvant–adjuvant targeted therapy in borderline resectable stage IIIB–D and IV melanoma;Cancer;2024-06-06

2. The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma;Cancers;2023-06-26

3. 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients;Clinical Nuclear Medicine;2022-04-22

4. Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma;Cancers;2021-12-27

5. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration;Journal of Tissue Engineering and Regenerative Medicine;2021-10-09